Disease relevance of Disease Models, Animal

• The most potent and selective compound, 4a (IC(50) = 2 nM), is an orally active, competitive, and apparently irreversible inhibitor of SSAO that is effective at reducing disease incidence and severity in an in vivo animal disease model of multiple sclerosis [1].
• Spinal cord axons and terminals stained for serotonin-like immunoreactivity were examined in rats and guinea-pigs with experimental allergic encephalomyelitis, an animal disease model for multiple sclerosis [2].
• OPG also inhibits bone resorption in a variety of animal disease models, including ovariectomy-induced osteoporosis, humoral hypercalcemia of malignancy, and experimental bone metastasis [3].

High impact information on Disease Models, Animal

• Recent studies have suggested that the proliferative effects of p21(ras) may depend on signaling outputs from the small Rho GTPases, Rac and Rho, but the physiologic importance of these interactions in an animal disease model has not been established [4].
• Different kinds of PDGF antagonists are currently being developed and evaluated in different animal disease models, as well as in clinical trials [5].
• A number of pharmaceutical companies have developed potent, orally active, nonpeptide endothelin receptor antagonists with efficacies in a wide variety of animal disease models and potential for treating human disease [6].
• Recent investigations on animal disease models using blocking antibodies to IL-8 have revealed the essential involvement of IL-8 in acute inflammation [7].
• The ratio of 8-dehydrocholesterol to 7-dehydrocholesterol is higher in human SLO than in the animal disease model [8].

Chemical compound and disease context of Disease Models, Animal

• Spinal cord axons and terminals stained for tyrosine hydroxylase-, serotonin- and substance P-like immunoreactivity were examined in guinea-pigs in the paraplegic phase of acute experimental allergic encephalomyelitis, an animal disease model for multiple sclerosis [9].
• Development of selective inhibitors of 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-1 and their use in rodent animal disease models encompassing several aspects of metabolic syndrome indicate the possibility of therapeutic intervention [10].
• Two widely employed ROCK inhibitors, fasudil and Y-27632, have provided preliminary but compelling evidence supporting the potential cardiovascular benefits of ROCK inhibition in preclinical animal disease models and in the clinic [11].

Biological context of Disease Models, Animal

• Our results suggest that in vivo ESR could be applied to the assessment of antioxidant effects on oxidative stress in the brain in animal disease models, such as the SHRSP [12].

Gene context of Disease Models, Animal

• Studies using the IL-1ra to block endogenous IL-1 in a variety of animal disease models suggest that IL-1 plays a key role in triggering the cascade of inflammatory responses [13].
• Experimental allergic encephalomyelitis (EAE) is considered the animal disease model for multiple sclerosis (MS) in humans [14].

References